Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kamada has announced that the company will soon start Phase II clinical trials with the inhaled version of its Alpha-1 Antitrypsin product to treat Bronchiectasis, a lung disease that results in the distortion of one or more of the conducting bronchi or airways, most often secondary to an infectious process.
Subscribe to our email newsletter
The study will be conducted using an eFlow Electronic Nebulizer optimized for delivery of Kamada’s Alpha-1 Antitrypsin (AAT) product. Kamada’s inhaled AAT has been designated an orphan drug for the treatment of CF and AAT Deficiency, in both Europe and the US.
David Tsur, CEO of Kamada, said: “We believe that, pending the successful completion of the trials and registration process, this formulation will both considerably improve the quality of life and extend the life expectancy of a wide range of Bronchiectasis patients.”